Traders overwhelmingly back an 80–90 flu hospitalizations per 100,000 population rate for Week 11 (late February–early March 2026), with 97.9% implied probability, driven by CDC FluView data showing the 2025–26 season's cumulative rate tracking moderate historical precedents like 2021–22 (peaking at 85 per 100k by mid-March). Declining test positivity (below 10%) and high vaccine strain match against dominant H1N1 and H3N2 clades support stabilization, as respiratory virus interference from lingering RSV wanes. Scenarios challenging this include a late-season clade shift boosting severity in elderly cohorts or underreported Southern Hemisphere spillover, potentially spiking new weekly admissions toward 100+, though models from NOAA-linked climate data forecast mild winter conditions limiting surges.
基于Polymarket数据的AI实验性摘要 · 更新于Flu Hospitalization Rate Week 11, 2026?
Flu Hospitalization Rate Week 11, 2026?
80–90 97.8%
100+ 1.6%
60–70 1.6%
<60 1.3%
<60
1%
60–70
2%
70–80
1%
80–90
98%
90–100
1%
100+
2%
80–90 97.8%
100+ 1.6%
60–70 1.6%
<60 1.3%
<60
1%
60–70
2%
70–80
1%
80–90
98%
90–100
1%
100+
2%
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
市场开放时间: Mar 20, 2026, 2:29 PM ET
Resolver
0x69c47De9D...Resolver
0x69c47De9D...Traders overwhelmingly back an 80–90 flu hospitalizations per 100,000 population rate for Week 11 (late February–early March 2026), with 97.9% implied probability, driven by CDC FluView data showing the 2025–26 season's cumulative rate tracking moderate historical precedents like 2021–22 (peaking at 85 per 100k by mid-March). Declining test positivity (below 10%) and high vaccine strain match against dominant H1N1 and H3N2 clades support stabilization, as respiratory virus interference from lingering RSV wanes. Scenarios challenging this include a late-season clade shift boosting severity in elderly cohorts or underreported Southern Hemisphere spillover, potentially spiking new weekly admissions toward 100+, though models from NOAA-linked climate data forecast mild winter conditions limiting surges.
基于Polymarket数据的AI实验性摘要 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题